Company: ABUS
Filing Date: 2025-11-13
Form Type: 10-Q
Source: 0001447028-25-000126
Chunk: 31

Company: Arbutus Biopharma Corp
Filing Date: 2025-11-13
Form: 10-Q
Item: Part I, Item 1
Chunk 31
---
(1)38,011 US government bonds30,197 27 (3)30,221 Total$71,237 $61 $(4)$71,294  (1) Gross unrealized gain (loss) is pre-tax and is reported in accumulated other comprehensive income (loss). Amortized CostGross Unrealized Gain(1)Gross Unrealized Loss(1)Fair ValueAs of December 31, 2024(in thousands)Cash equivalentsMoney market funds$29,533 $— $— $29,533 Total$29,533 $— $— $29,533 Investments in marketable short-term securitiesUS corporate bonds$30,776 $27 $(6)$30,797 US treasury bills55,467 29 — 55,496 Total$86,243 $56 $(6)$86,293 (1) Gross unrealized gain (loss) is pre-tax and is reported in accumulated other comprehensive income (loss).The contractual term to maturity of the $71.3 million of short-term marketable securities held by the Company as of September 30, 2025 is less than one year. As of September 30, 2025, the Company held no long-term marketable securities.  As of December 31, 2024, the Company’s $86.3 million of short-term marketable securities had contractual maturities of less than one year, while the Company held no long-term marketable securities.At September 30, 2025 and December 31, 2024, the Company had 8 and 6, respectively, available-for-sale investment debt securities in an unrealized loss position without an allowance for credit losses. Unrealized losses on the Company’s investments in debt securities have not been recognized into income as the issuers’ securities are of high credit quality and the decline in fair value is largely due to market conditions and/or changes in interest rates. The Company does not intend to sell and it is more likely than not that the Company will not be required to sell the securities prior to the anticipated recovery of their amortized cost basis. The issuers continue to make timely interest payments on the securities. The fair value is expected to recover as the securities approach maturity. Accrued interest receivable on investments in marketable securities of $0.3 million at September 30, 2025 and December 31